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Abstract
Massive tissue remodelling occurs within the mammary gland
during pregnancy, resulting in the formation of lobuloalveoli that are
capable of milk secretion. Endocrine signals generated
predominantly by prolactin and progesterone operate the alveolar
switch to initiate these developmental events. Here we review the
current understanding of the components of the alveolar switch
and conclude with an examination of the role of the ets
transcription factor Elf5. We propose that Elf5 is a key regulator of
the alveolar switch.
Introduction: the alveolar switch
Massive tissue remodelling within the mammary gland during
pregnancy results in the formation of the secretory
lobuloalveolar units in preparation for lactation. The initial
proliferative phase of alveolar morphogenesis is instigated by
an increase in the level of serum prolactin (Prl) and
progesterone (Pg) [1]. These hormones activate the alveolar
switch, a genetic program that coordinates changes in
mammary epithelial cell proliferation, migration, differentiation
and deletion within the many tissue types of the mammary
gland. Here we review our current understanding of the
genetic program controlling alveolar morphogenesis, using
the mouse as a model of the human breast [2]. We then
examine the role played by the ets transcription factor Elf5 in
coordinating this program in epithelial cells, and propose that
Elf5 is a central component of the alveolar switch.
Tissue remodelling during pregnancy
The most striking aspect of mammary development during
pregnancy is massive tissue remodelling. During the alveolar
morphogenesis phase [3], rapid and global proliferation of
the epithelial cells occurs within the ductal branches and
developing alveoli. This increases both epithelial cell number
and epithelial surface area, actions essential for sufficient milk
production during lactation. Cell differentiation becomes
dominant from mid-pregnancy as the gland moves into the
secretory initiation phase [3]. The developing alveoli cleave
and the alveolar cells become polarised and form a sphere-
like single layer of epithelial cells that envelopes a circular
lumen, connected to the ductal network via a single small
duct. Each individual alveolus is surrounded by a basket-like
architecture of contractile myo-epithelial cells. The myo-
epithelium of the alveoli is discontinuous so that the luminal
cells directly contact the underlying basement membrane,
which forms part of the extracellular matrix. Some cells of the
ductal network also contact the basement membrane.
Contact is required for complete lobuloalveolar differentiation
[4,5], seen morphologically by the appearance of lipid
droplets [6] and by the initiation of gene expression in a
defined order [7]. Nearing parturition, alveolar tight junctions
close and milk and colostrum proteins move into the alveolar
lumen, in preparation for active milk secretion post-partum,
which marks the onset of the secretory activation phase [8]
(Figure 1).
The epithelial expansion is paralleled by equally dramatic
changes in other tissue compartments. Adipocytes lose their
lipid content and remain as long projections scattered
throughout the alveolar epithelium [9]. A huge expansion of
the vasculature also occurs within the stroma, to provide the
large quantities of energy, sugars, amino acids and solutes
required for milk production [10]. Developmental events are
also elicited elsewhere in the animal; for example, the gut and
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liver enlarge dramatically to cope with the energy needs of
gestation and lactation. The brain is programmed for correct
maternal behaviour by Prl [11]. Thus, the alveolar switch is
part of a larger mechanism controlling all aspects of
adaptation to pregnancy and lactation.
Another striking aspect of tissue remodelling during
pregnancy is its cyclical nature. Following weaning nearly all
of the development induced by the alveolar switch is removed
by programmed cell death during the involution phase, only to
redevelop with the next pregnancy. This observation first led
researchers to hypothesise that mammary tissue must
contain persistent self-renewing mammary stem cells
(reviewed in [12]). The ability of small epithelial transplants to
recapitulate a complete and fully functional epithelial
mammary gland reinforced this view [13]. The presence of a
single mammary stem cell was indicated by limiting dilution
experiments and the existence of committed progenitor cells
was demonstrated by transplants that showed limited
developmental capacity [14]. This cell was recently isolated
and elegantly demonstrated to be capable of producing a
renewable and complete mammary epithelium [15]. Thus it is
hypothesised, based on a paradigm developed in the
hematopoietic system, that a primary mammary epithelial stem
cell gives rise to a hierarchy of epithelial progenitor cell
lineages to ultimately produce the different cells found in the
mammary epithelium [16,17]. The flux of cells through these
lineages is likely to be controlled by, and in turn control, the
patterns of gene expression that comprise the alveolar switch.
Integrating our knowledge of gene expression patterns with
the emerging knowledge regarding stem cell lineages and
their interactions offers us an unprecedented opportunity to
understand this phase of mammary development.
Prolactin and progesterone initiation of
alveolar morphogenesis
The formation of the milk secreting structures during
pregnancy is dependent on a synergy between Prl and Pg
signalling [6]. These hormones trigger an initial wave of cell
proliferation during days two to six of pregnancy [18]. The
progesterone receptor (Pgr) knockout mouse demonstrated
that Pg is required for alveolar morphogenesis, and epithelial
recombination experiments demonstrated that Pgr in the
mammary epithelium, not the stroma, was essential for
Figure 1
Alveolar morphogenesis. Mammary wholemounts (Carmine alum stain top row) and mammary cellular architecture (low power, middle row; high
power, bottom row) in virgin, 12 days posts coitus (dpc), 18 dpc and 1 day post partum (1 dpp) murine mammary glands. Ductal epithelial cells
(arrow) and myoepithelial cells (arrowhead) arise from a common mammary epithelial stem cell. Massive epithelial cell proliferation occurs at the
onset of pregnancy, which is co-ordinated predominantly by prolactin and progesterone. At mid-pregnancy (12 dpc), developing alveoli continue to
proliferate and polarise to form a sphere-like single layer of epithelial cells enveloping a circular lumen (indicated by X). This is followed by further
cell proliferation and differentiation categorised by the expression of milk genes and the formation of cytoplasmic lipid droplets (indicated by
asterisks). At 18 dpc, alveoli have large amounts of lipid and milk protein expression is increased. At parturition, tight junctions between alveolar
cells close and milk proteins and lipid are secreted into the alveolar lumen (X). An expansion of the vasculature (open arrows) and reduction in the
adipocyte (A) area is also apparent in the stroma.Page 3 of 10
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epithelial cell proliferation [19]. Not all mammary epithelial
cells express Pgr and, therefore, are unable to respond to Pg
directly. Mammary gland chimeras made from Pgr+/+ and
Pgr–/– mammary epithelial cells (MECs) demonstrated that
Pgr–/– epithelial cells proliferate in response to Pg and,
therefore, must respond to a paracrine factor from Pgr+/+
cells [1]. Indeed, in the epithelium, proliferating cells
segregate with Pgr positive cells [20]. This is also true for
estrogen receptor positive cells [21]. Further, steroid
receptor positive cells are in close proximity to proliferating
cells, indicating that proliferation is mediated, at least in part,
by a paracrine mechanism. This heterogeneous receptor
patterning observed in the luminal epithelium is required for
complete lobuloalveolar development [22].
Wingless-related MMTV integration site 4 (Wnt4) and
receptor activator of nuclear factor (NF)-κB ligand (RankL)
are targets of the Pgr signalling pathway and may be the
paracrine factors responsible for cellular proliferation in
steroid receptor negative cells. Over-expression of the proto-
oncogene Wnt1 can rescue pregnancy-induced ductal side
branching in Pgr knockout mice, indicating that a Wnt factor
may be an important paracrine mediator of Pg-induced ductal
side branching during early pregnancy [23]. Mammary
transplants of Wnt4–/– epithelium have demonstrated that
Wnt4 acts in a paracrine fashion to stimulate epithelial ductal
side branching during early pregnancy. In these experiments,
normal lobuloalveolar proliferation was observed during the
later half of pregnancy, indicating that other factors mediating
proliferation in late pregnancy may be involved [23].
The RankL target, NF-κB, is required for cyclin D1 (Ccnd1)
activation via the kinase IκB (IKKα) in neighbouring
proliferating cells. Germ line deletion of both RankL and its
receptor (Rank) in mice resulted in failed alveolar
morphogenesis due to reduced proliferation and increased
apoptosis of alveolar epithelial cells [24]. These effects were
mediated by protein kinase B (PKB/Akt), demonstrating that
this pathway is essential for the formation of lobuloalveolar
structures [24]. The RankL/NF-κB/Ccnd1 pathway is now
known to be crucial for the formation of alveolar structures
during pregnancy [25], and NF-κB is essential for Pg driven
proliferation within alveoli [20]. RankL also co-localises with
Pgrs in response to pregnancy levels of estrogen and Pg,
indicating this is an important part of the response. In primary
MEC cultures, Pg acts in synergy with estrogen to increase
Ccnd1 transcription, resulting in increased proliferation [26].
Together, these data indicate that Pg may drive the
proliferation of neighbouring cells via RankL/NF-κB, resulting
in Ccnd1 transcription (Figure 2a,b). Pgr consists of two
isoforms, PgrA and PgrB, which are expressed from a single
gene. The PgrB isoform is essential and sufficient for alveolar
morphogenesis during pregnancy. Alveoli in PgrB knockout
mice fail to develop due to impaired proliferation of the ductal
and alveolar compartment, which is possibly mediated via
activation of RankL [27].
Pituitary Prl stimulation of ovarian Pg assists in maintaining
the required levels of Pg during early pregnancy [28]. In
addition, up-regulation of Pgr expression by Prl, and Prl
receptor (Prlr) expression by Pg, suggests that these
hormones may interact in a synergistic manner to control
alveolar development. Prolactin receptor knockout mice
(Prlr–/–) have demonstrated the importance of this receptor
during mammary development [29]. Like Pgr, experiments
with Prlr–/– mice have shown that the presence of Prlr in the
epithelial cells, not the stroma, is essential for normal
lobuloalveolar differentiation [30]. Prlr–/– mammary
transplants fail to develop lobuloalveoli and produce milk
proteins during pregnancy, illustrating that Prlr is essential in
the mammary epithelium during alveolar morphogenesis. The
downstream targets of prolactin signalling will be discussed
in more detail later in this review.
The neuronal peptide galanin (Gal) regulates Prl secretion
from the pituitary lactotrophs [31]. In addition, the mammary
epithelium is responsive to Gal, as it augments alveolar
morphogenesis in mammary explants in the presence of Prl
[32]. Gal–/– mice show increased levels of the inhibitory
phosphorylated form of Prl [33], and are unable to nurse
pups due to failed secretory activation [34]. Therefore, Gal
has dual actions: firstly, an indirect role by modulating
pituitary Prl and phosphorylated Prl release; and secondly, a
direct cell autonomous role in the formation of lobuloalveoli
during pregnancy.
Other hormones can influence alveolar morphogenesis.
Growth hormone may act in combination with Prl to mediate
alveolar proliferation. Growth hormone treatment restores
alveolar morphogenesis but inhibits lactation in Prlr+/–
mammary glands [35]. Placental lactogen is released from
the placenta during pregnancy and can fully compensate for
Prl, allowing alveolar morphogenesis in Prl–/– mice [36].
Molecular modulators of Prl induced alveolar
morphogenesis
Members of the Prl-signalling pathway are essential for
normal alveolar morphogenesis [37]. Prlr dimerization occurs
after Prl binding and leads to the phosphorylation of the
associated Janus kinase (Jak2) [38,39], which in turn
phosphorylates specific residues on the Prlr [40]. Stat5 is
then recruited to the receptor and is phosphorylated by Jak2
[41]. Phosphorylated Stat5 is then translocated to the
nucleus where it can activate transcription of multiple genes
[42] involved a variety of processes during alveolar
morphogenesis, including establishment of epithelial polarity
and cell-cell interactions, stromal epithelial interactions and
milk protein expression during lactation (Figure 2c). Both
isoforms of Stat5, Stat5a and Stat5b, when knocked out in
mice, result in lobuloalveolar defects [43-45]. The phenotype
is more severe in combined Stat5a/Stat5b knockout animals.
One class of genes activated by the prolactin-signalling
pathway are the suppressor of cytokine signalling (Socs)
Available online http://breast-cancer-research.com/content/8/2/207members, which act to shut down the Prl-signalling pathway.
Socs1 knockout mice show precocious development during
pregnancy, and Socs1+/– mice can restore the lobuloalveolar
defects present in Prlr+/– mice due to Prlr haplo-insufficiency
[46]. Similarly, loss of Socs2 can also rescue lactation in
Prlr+/– females [47].
Transcript profiling of Prlr knockout mammary glands
identified a panel of genes that require Prlr-mediated
signalling for increased expression during early pregnancy
[46,48] (Figure 2c). Two members of the collagen family and
laminin were identified. These molecules are cell adhesion
components of the extracellular matrix and play an important
part in the epithelial-stromal signalling required for full
lobuloalveolar differentiation and gene expression [4,7].
Alveolar morphogenesis induced by Prl involves the
establishment of polarity and cell-cell communication. The
maintenance of cellular polarity is regulated by the closure of
tight junctions, and the expression of tight junction proteins
Claudin-3 and Claudin-7 was reduced in Prlr–/– mammary
transplants [46]. The gap junction protein Connexin 26 was
also identified and is involved in the exchange of small ions
and metabolites [49]. Recently, Connexin-26 was shown to
be important in full lobuloalveolar development and in the
prevention of alveolar cellular apoptosis [50].
Wnt4 was also down-regulated in Prlr–/– transplants,
indicating that it is potentially a target of Prlr signalling [46].
The downstream target of Wnt, β-catenin, has specific actions
in both the luminal and myoepithelial compartments of the
epithelium, and as a component of cell-cell junctions appears
to have a role in signalling to luminal epithelial cells [51,52].
Indeed, activation of β-catenin within the basal epithelial cells
results in premature differentiation of the luminal epithelium
during pregnancy and persistent proliferation resulting in
tumors. These tumors consisted predominantly of
undifferentiated basal cells, which were amplified in response
to β-catenin activation, thereby implicating this molecule in cell
fate decisions in the mammary gland [52].
The gene encoding RankL was also identified as potentially
regulated by Prl [46,53]. Ccnd1 null mutants exhibit
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Figure 2
Molecular control of alveolar morphogenesis. Signalling from the progesterone receptor (Pgr) and prolactin receptor (Prlr) is essential for alveolar
morphogenesis in pregnancy. Increases in serum progesterone (Pg) and prolactin (Prl) result in luminal cell proliferation during early pregnancy,
which continues throughout gestation. (a,b) Heterogenous receptor patterning is essential for complete alveolar morphogenesis. (a) Transforming
growth factor (Tgf)-β1 signalling via phosphorylation of Smad results in the transcription of target genes, which act to control proliferation in steroid
receptor positive cells. Wnt4 and RankL are transcribed in response to Pgr signalling, probably in cooperation with Prl signalling, and appear to
stimulate proliferation of neighbouring cells via paracrine mechanisms. (b) RankL binds to its receptor Rank in a neighbouring cell and activates the
RankL/nuclear factor (NF)-κB pathway, resulting in cyclin-D1 (Ccnd1) transcription and proliferation. Wnt4 binds and activates its target β-catenin,
which has specific roles for both luminal and myo-epithelium for cell fate decisions involving both proliferation and differentiation. (a,c) Prl binds to
Prlr and activates the Jak2/Stat5 cascade, resulting in the transcription of genes, including various transcription factors (TF) involved in epithelial
morphogenesis and branching (Wnt4), establishment of epithelial polarity and cell-cell interactions (claudins and connexins), stromal epithelial
interactions (collagen and laminin), proteins that regulate their own pathway (Socs1/2) and lactation (serotonin and milk proteins). Prl signalling
also results in the transcription of cyclin D1 via an insulin growth factor 2 dependent mechanism. The ets transcription factor Elf5, transcribed in
response to Prl, can completely compensate for the loss of Prlr signalling. Laminin in the extracellular matrix binds to β1-integrin when contact
between the basement membrane and the luminal epithelium is established, and is essential for the maintenance of alveolar cell polarity and
differentiation. ErbB4 and its ligands complement Prlr signalling as activation of ErbB4 results in Stat5 phosphorylation and translocation to the
nucleus. GJ, gap junction; L, lipid droplet; TJ, tight junction.significantly delayed alveolar cell proliferation and impaired
lactation, which was shown to be epithelial cell autonomous
[54]. Interestingly, Prl can induce Ccnd1 expression via
induction of insulin growth factor 2, independent of RankL
induction [55]. The similarities between Prl- and Pg-mediated
effects on both RankL and Wnt signalling is further evidence
of the co-operation of these pathways for alveolar cell
proliferation during early pregnancy (Figure 2a).
Gene expression profiling of Prl–/– mice has also identified
unique targets of mammary development. Expression of
tryptophan hydroxylase, the rate-limiting enzyme in serotonin
biosynthesis, is increased by Prl during pregnancy and
lactation. Accumulation of serotonin due to milk engorgement
experienced during weaning or experimentally via teat sealing
inhibits milk gene expression and can induce involution,
providing a mechanism that is put in place by Prl to stop
lactation at weaning [56].
Transcription factors involved in alveolar
morphogenesis
Prl and Pg and other factors induce the transcription of
genes via activation of target transcription factors. These
include Stat5 and the steroid hormone receptors as
discussed previously, which bind to DNA and result in the
transcription of genes involved in many aspects of alveolar
morphogenesis. Further, some of these target genes are
transcription factors also, which act to induce the expression
of genes or groups of genes involved in lobuloalveolar
development. An example is the transcription factor Srebf1,
which was identified from transcript profiling experiments on
three mouse models of failed secretory activation [33].
Srebf1 controls the expression of a number of key lipid
metabolism genes [57] that showed reduced expression
concomitantly with decreased Srebf1 expression [33]. Some
transcription factors that appear to be involved in alveolar
morphogenesis include the homeobox genes, helix-loop-helix
genes, Stats, Tcf/Lef family, NF-κB, the Ceb/p family, the
nuclear factor family and the Ets transcription factors. The
regulation of cellular proliferation during mammary develop-
ment by the homeobox genes, helix-loop-helix genes, stats
and ets transcription factors has been reviewed previously [58].
Pg and Prl are hypothesised to influence the expression of β-
catenin via induction of the Wnt pathway, as discussed
earlier. β-Catenin regulates the activity of the Tcf/Lef family of
transcription factors, which appear to mediate β-catenin
signalling and, therefore, may play a role during alveolar
morphogenesis [59]. Inhibition of β-catenin results in alveolar
apoptosis and greatly reduced milk production capacity. Mice
lacking Lef-1 demonstrate a failure to form the alveolar bud at
embryonic day 13. The expression of Lef-1 was co-expressed
with  β-catenin, and shows a similar expression pattern in
response to parathyroid hormone-related protein [60]. Thus,
Lef-1 may act to mediate the actions of β-catenin, although its
effects during alveolar morphogenesis are still unclear.
The NF1 family of transcription factors also play a role in
functional differentiation as they regulate the transcription of
milk protein genes such as those encoding whey acidic
protein, α-lactalbumin and β-lactoglobulin [61]. The NF1-C2
isoform member of this family induces the expression of the
milk genes encoding carboxyl ester lipase and whey acidic
protein. Prl regulates the protein expression of NF1-C2 in
NmuMG cells, and its expression is reduced in the nucleus of
Prlr–/– luminal cells at mid-pregnancy, indicating that NF1-C2
may be regulated by Prl signalling during pregnancy and
involved in expression of milk genes in preparation for
lactation [62].
The helix-loop-helix transcription factors Id1 and Id2 have
varying expression in the mammary gland. Id1 expression is
increased during early pregnancy, remains low during
lactation and rises again at involution. Unlike Id1, Id2 remains
high during lactation, indicating that these isoforms have
specific functional roles during alveolar morphogenesis [63].
Id1 is specifically expressed by the expanding epithelium
during the alveolar proliferative phase and is inversely
correlated with the expression of β-casein; it appears,
therefore, to be an important factor during early alveolar
proliferation. Id1 also regulates Clusterin, which is involved in
the regulation of cell-cell interactions. Additionally,
lobuloalveolar development is severely impaired in Id2
knockout mice. Reduced proliferation and increased
apoptosis has been observed in mammary epithelium lacking
Id2, resulting in the failure to form alveolar structures and
consequently failure of lactation [64]. Id2 also promotes
differentiation in MEC cultures, indicating Id2 is essential for
the differentiation of the mammary epithelium [63].
The transcription factor NF-κB discussed earlier in this review
is essential for Pg induced alveolar cell proliferation resulting
in Ccnd1 transcription [20,25]. NF-κB can also induce the
transcription of many genes involved in the regulation of
apoptosis. NF-κB levels are induced during pregnancy,
decline during lactation and are re-induced during lactation
implying a role in mammary gland remodelling. It is also
hypothesised that NF-κB is an essential ‘checkpoint’ of
apoptosis, whose actions are dependent on association with
specific transcriptional regulators. Thus NF-κB is an
important transcription factor controlling both proliferation
and apoptosis in the epithelium during pregnancy [65].
The C/ebp family of proteins appear to be important
regulators of alveolar morphogenesis (for a review, see [66]).
C/ebpβ and C/ebpδ isoforms are increased during
pregnancy and decline during lactation, indicating that they
play a critical role in alveolar morphogenesis and early milk
gene expression. Transplantation experiments have revealed
that C/ebpβ is required in epithelial cells for normal
lobuloalveolar development during pregnancy, and C/ebpβ
knockout mice display phenotypes similar to Pgr, Prlr,
Stat5a/b, Ccnd1, Id2 and RankL knockouts [66]. Interestingly
Available online http://breast-cancer-research.com/content/8/2/207
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glands of C/ebpβ null mice and, in addition, the expression of
Pgr was unusually uniform within the epithelium [67]. These
effects were associated with a 10-fold decrease in the rate of
proliferation. There was, however, no change in the
expression of C/ebpβ in the mammary glands of Pgr
knockout mice, indicating that C/ebpβ is upstream of Pgr and
possibly controls the spatial distribution of epithelial cells,
which influence proliferation in alveolar progenitors [67].
C/ebpβ null epithelium significantly increased Tgf-β and
Smad2 signalling, and this pathway is known to inhibit cellular
proliferation [68]. Cell cycle progression in C/ebpβ null
MECs was blocked at the G1/S transition, preventing these
cells from proliferating in response to early pregnancy levels
of Pg and estrogen [69]. Therefore, C/ebpβ is essential for
controlling cell fate decisions within the mammary gland,
including attenuating Pgr expression resulting in mammary
epithelial cell differentiation during pregnancy.
The expression of the Ets transcription factor subfamily Pea3
is elevated at the onset of pregnancy but declines during mid-
pregnancy to low levels at lactation and involution, suggesting
a role in early pregnancy induced ductal outgrowth. Three
members of the Pea3 subfamily are expressed by both the
myoepithelium and the luminal cells, although their expression
varies during pregnancy, suggesting multiple signalling roles
during alveolar morphogenesis. The expression of all members
of the family remains in the myoepithelium during pregnancy,
although the expression of the ER81 member declines in the
luminal epithelium seven days after impregnation. Increased
numbers of dividing cells were observed in the terminal end
buds of Pea3 knockout mice, and mammary gland transplants
of Pea3 knockout epithelium displayed reduced mammary
branching during pregnancy, suggesting a role for Pea3 in
progenitor cell differentiation [70].
Other factors involved in alveolar
morphogenesis
The receptor tyrosine kinase ErbB (epidermal growth factor)
family and their ligands are important mediators of all aspects
of mammary development. There are four receptors: epidermal
growth factor receptor/ErbB/Her1, ErbB2/Her2/neu, ErbB3/
Her3 and ErbB4/Her4, which are activated by a variety of
ligands inducing activation via dimerisation and cross
phosphorylation. ErbB ligands share a 50 amino acid domain,
which is homologous to epidermal growth factor. Mice
expressing a truncated dominant negative allele of ErbB2 did
not exhibit a phenotype until late pregnancy, when alveoli
failed to expand and distend, indicating that ErbB2 is critical
for secretory activation, and will be discussed later in this
review series [71]. Conditional deletion of ErbB4 within the
mammary gland at pregnancy demonstrated a critical role for
this receptor during alveolar morphogenesis [72]. Alveolar
expansion was reduced from 13.5 days post coitus in
mammary epithelium lacking ErbB4, resulting in incomplete
alveolar development and failure to nurse pups due to
reduced milk gene expression. Alveolar proliferation was
attenuated and Stat5 phosphorylation was abolished. The
ErbB4 ligand neuregulin/heregulin-1 (Nrg) promotes lobulo-
alveolar development and the expression of milk genes when
used in mammary gland explants [73], indicating a role for
this ligand in lobuloalveolar development. In addition, mice
that lack the alpha form of Nrg show a similar phenotype to
ErbB4 knockout, with reduced alveolar proliferation and
differentiation, demonstrated by reduced β-casein expression
in reduced alveoli expansion [74].
Other ErbB ligands also appear to have overlapping functions
for mammary gland development. Amphiregulin null animals
have reduced alveolar development, although the phenotype
was much more severe in a triple mutant including knockouts
of Tgfα and epidermal growth factor (all ligands of the ErbB
family), indicating overlapping and compensatory roles for
these ligands during alveolar morphogenesis [75]. Triple
mutants developed poorly organised and differentiated alveoli,
had reduced milk protein expression and often pups born to
these mice did not survive. Amphiregulin loss was also
associated with reduced Stat5 phosphorylation. Our transcript
profiling experiments demonstrated that amphiregulin was
down-regulated in Prlr–/– epithelium [46], indicating that
amphiregulin may be modulated by Prlr signalling. These data
together indicate important roles for the ErbB receptors and
ligands during alveolar morphogenesis. The overlapping
phenotypes observed in Prlr, Pgr and ErbB knockout mice
suggest there may be some cross-talk between these
receptors, which is yet to be fully understood.
The cell surface receptor β1 integrin, which is present on
luminal epithelial cells, is an essential mediator of extracellular
matrix signalling via its ligands collagen and laminin [76].
Mammary epithelium in mice lacking β1 integrin in the luminal
cells, displayed reduced proliferation and alveolar
disorganisation [77]. The focal adhesion kinase, which is
important in protein complexes that connect the extracellular
matrix to the actin cytoskeleton, was also reduced in these
mice. Conditional deletion of β1 integrin during early
pregnancy and late pregnancy demonstrates that this
molecule was important for both the formation of
lobuloalveolar structures and for functional differentiation
[78]. In these mammary glands, luminal epithelium becomes
dissociated from the basement membrane, and cellular
polarity is compromised as luminal epithelial cells protrude
into the alveolar luminal space. In addition, Prl-stimulated milk
protein expression via phosphorylation of Stat5 was largely
absent in primary mammary epithelial cells lacking β1-integrin,
indicating that it is essential for Prl-induced activation of
Stat5 [79].
The cytokine Tgf-β1 is an important regulator of mammary cell
proliferation during pregnancy [68]. Tgf-β1 is restricted to the
luminal epithelial cells and can control cell proliferation via
phosphorylation of Smad following Tgf-β receptor activation
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alveolar development due to increased proliferation, indicating
that the expression of Tgf-β1 restricts alveolar cell
proliferation. Epithelial cell proliferation was increased more
than 15-fold in Tgf-β1 null ovariectomised animals treated
with estrogen and Pg compared to wild-type mice [81]. In
animals treated with estrogen and Pg, Tgf-β1 expression was
restricted to the steroid receptor positive epithelial cells,
indicating that Tgf-β1 may play an important role in restricting
epithelial cell proliferation in these cells [82].
The ets transcription factor Elf5
Our transcript profiling experiments identified a number of
transcription factors that showed reduced expression in
response to a loss of Prlr, but profiling of a cell based model
of positive Prl action identified the ets transcription factor Elf5
[47]. Ets transcription factors are identified by a highly
conserved DNA binding domain (the ets domain), which
binds to sites containing a central GGA motif [83]. Ets
transcription factors regulate gene expression during the
differentiation of multiple tissues including vascular, lymphoid,
muscle and bone (reviewed in [84]). Elf5 (e74-like factor 5 or
ESE-2) is an epithelial specific member of the Elf subfamily of
Ets transcription factors, and is closely related to the
epithelial specific Elf3 (ESE-1) and Ehf (ESE-3) [85,86]. The
predicted protein products of mouse Elf5 and human ESE-2
are 95% identical and are expressed as two isoforms
produced by alternative start sites. Such high conservation of
sequence implies similar conservation of function [86].
Elf5 is expressed specifically in the luminal cells of mammary
tissue [47], and its expression is increased dramatically
during pregnancy, to levels that far exceed those seen in
other tissues. Elf5 can also bind to an ets-like domain in the
proximal promoter of whey acidic protein and induce its
expression independently of lactogenic hormones, indicating
that Elf5 may be an important mediator of alveolar
differentiation during mid-pregnancy [87]. Elf5–/– mice die in
utero due to a placentation defect [88]. Elf5+/– mice did not
lactate due to failed alveolar development and, in some mice
where alveoli had formed, differentiation into functional
secretory units was severely impaired [89]. Mammary
epithelial cell proliferation was reduced throughout alveolar
morphogenesis and secretory activation, and mammary
epithelial transplants demonstrated that this effect was cell
autonomous. The levels of Elf5 are reduced in Prlr+/– glands
and there is no similar reduction in the expression of Prlr in
Elf5+/–, indicating that Elf5 is downstream of the Prlr [89].
MECs from Prlr–/– mammary glands fail to form lobuloalveoli
during pregnancy when transplanted into the cleared fat pad
of hosts with a normal endocrine milieu. Retroviral re-
expression of Elf5 in Prlr–/– MECs followed by transplantation
to a cleared fat pad resulted in a rescue of alveolar
morphogenesis [47]. MECs expressing high levels of Elf5
proliferated and differentiated into distended, milk filled alveoli
[47]. Thus, re-expression of Elf5 in Prlr–/– MECs could
completely compensate for the loss of the Prlr signalling
cascade. Prlr–/– MECs expressing lower levels of Elf5
showed development that passed alveolar formation but
failed during secretory initiation, mimicking the situation seen
in Elf5+/– and Prlr+/– mice. Elf5 is a key mediator of structural
and functional development of lobuloalveoli [47]. Elf5 would
thus appear to be a master-regulator of the alveolar switch
required for alveolar morphogenesis.
Conclusion
It is apparent that a large number of genes can influence
alveolar morphogenesis during pregnancy, some of which are
shown in Figure 2. A better understanding of the components
of the alveolar switch, and thus the regulation of mammary
cell proliferation and differentiation, has direct application to
the regulation of lactation in agricultural species and the
prevention and control of breast cancer. The key question is
how the expression of these numerous proteins is organised
and regulated by the alveolar switch. One potential model is a
hierarchy of transcription factors that are each responsible for
regulating an aspect of development. A precedent for this
model is provided by the action of the transcription factor
Srebf1, which regulates the expression of lipogenic enzymes
during secretory initiation [33]. In this model, Elf5 would be
placed close to the origin of the hierarchy, as a master
regulator of the transcriptional cascade controlling alveolar
morphogenesis.
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